Sectoral Asset Management Lowered Incyte (INCY) Stake, RCM Technologies (RCMT)’s Sentiment Is 1.4

July 13, 2017 - By Stephen Andrade

Sectoral Asset Management Inc decreased Incyte Corporation (INCY) stake by 84.63% reported in 2016Q4 SEC filing. Sectoral Asset Management Inc sold 189,289 shares as Incyte Corporation (INCY)’s stock rose 9.08%. The Sectoral Asset Management Inc holds 34,374 shares with $3.45 million value, down from 223,663 last quarter. Incyte Corporation now has $27.20 billion valuation. The stock declined 1.28% or $1.7 reaching $131.52 per share. About 130,629 shares traded. Incyte Corporation (NASDAQ:INCY) has risen 72.84% since July 13, 2016 and is uptrending. It has outperformed by 56.14% the S&P500.

RCM Technologies, Inc. is a provider of business and technology solutions. The company has market cap of $62.89 million. The Firm is also a well-known provider of specialty healthcare services to healthcare institutions and educational facilities. It has a 49.48 P/E ratio. The Firm operates through three divisions: Engineering, Information Technology and Specialty Health Care Services.

About 5,800 shares traded. R C M Technologies Inc (RCMT) has declined 6.74% since July 13, 2016 and is downtrending. It has underperformed by 23.44% the S&P500.

Heartland Advisors Inc holds 0.39% of its portfolio in R C M Technologies Inc for 1.10 million shares. Bourgeon Capital Management Llc owns 92,902 shares or 0.37% of their US portfolio. Moreover, Bard Associates Inc has 0.23% invested in the company for 79,595 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.02% in the stock. Rbf Capital Llc, a California-based fund reported 20,000 shares.

Among 20 analysts covering Incyte (NASDAQ:INCY), 18 have Buy rating, 0 Sell and 2 Hold. Therefore 90% are positive. Incyte had 51 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was initiated by Credit Suisse with “Outperform” on Wednesday, January 20. On Wednesday, July 5 the stock rating was maintained by Oppenheimer with “Hold”. JMP Securities maintained the stock with “Market Outperform” rating in Monday, October 10 report. Barclays Capital initiated the shares of INCY in report on Thursday, August 13 with “Overweight” rating. The rating was maintained by Oppenheimer on Monday, November 9 with “Outperform”. The firm earned “Buy” rating on Wednesday, September 2 by Brean Capital. The stock of Incyte Corporation (NASDAQ:INCY) has “Buy” rating given on Friday, February 12 by Brean Capital. The firm has “Outperform” rating given on Wednesday, October 12 by RBC Capital Markets. As per Tuesday, August 18, the company rating was maintained by Piper Jaffray. On Tuesday, June 20 the stock rating was maintained by Jefferies with “Buy”.

Investors sentiment increased to 1.23 in Q4 2016. Its up 0.08, from 1.15 in 2016Q3. It is positive, as 32 investors sold INCY shares while 130 reduced holdings. 66 funds opened positions while 133 raised stakes. 173.11 million shares or 1.04% more from 171.33 million shares in 2016Q3 were reported. American Gp Inc accumulated 16,890 shares. Reilly Financial Ltd Liability Com reported 0.01% stake. Qs Investors Limited Liability Co has invested 0% in Incyte Corporation (NASDAQ:INCY). Gardner Lewis Asset Mngmt Lp invested in 36,325 shares or 0.28% of the stock. Hood River Ltd Co accumulated 0% or 102 shares. First Mercantile Tru has 0.07% invested in Incyte Corporation (NASDAQ:INCY) for 4,669 shares. Lord Abbett And Comm Limited Liability Company stated it has 257,990 shares. Earnest Ptnrs Limited Co holds 0% or 73 shares. State Of Wisconsin Invest Board accumulated 81,823 shares. Torray Ltd, Maryland-based fund reported 180,511 shares. Blackrock Group Inc Ltd invested in 0.05% or 1.13 million shares. Loring Wolcott And Coolidge Fiduciary Advsrs Llp Ma holds 575 shares or 0% of its portfolio. Moreover, Cornerstone Advsrs Inc has 0.05% invested in Incyte Corporation (NASDAQ:INCY) for 614 shares. 1.19M are held by Ubs Asset Mngmt Americas. M&T Bancshares invested in 20,580 shares.

Sectoral Asset Management Inc increased Amicus Therapeutics (NASDAQ:FOLD) stake by 905,746 shares to 5.10M valued at $25.35M in 2016Q4. It also upped Biomarin Pharmaceutical Inc (NASDAQ:BMRN) stake by 80,783 shares and now owns 492,100 shares. Momenta Pharmaceuticals (NASDAQ:MNTA) was raised too.